8/102 sources · 2 publishersUpdated Nov 1, 18:57 UTC
Heartflow CT‑guided PCI trial shows non‑inferior outcomes and faster procedures
Heartflow presented data from its 1,105‑patient P4 randomized trial at TCT 2026, showing CT‑guided PCI planning was non‑inferior to intravascular ultrasound for one‑year target‑vessel failure. The CT‑guided arm achieved a median procedure time 17 minutes shorter and used about 12% less contrast. In the concurrent NAVIGATE‑PCI registry, physicians altered their treatment plans in roughly 70% of cases after reviewing the Heartflow PCI Navigator.
Why it matters
The company says the efficiency gains and comparable outcomes could accelerate adoption of its CT‑guided planning tool, potentially expanding its market and revenue streams.
Key facts
- 1The P4 trial enrolled 1,105 patients across 23 centers in the U.S., Europe, and Japan. stocktitan.net
- 2CT‑guided PCI was non‑inferior to IVUS for the primary endpoint of 12‑month target‑vessel failure (4.1% vs. 4.6%). stocktitan.net
- 3Median procedure time was 46 minutes for CT‑guided PCI versus 63 minutes for IVUS, a 17‑minute reduction. stocktitan.net
- 4Contrast volume was reduced by approximately 12% (median 150 mL vs. 170 mL). stocktitan.net
- 5Use of advanced calcium modification more than doubled in the CT‑guided arm (9.2% vs. 3.8%). stocktitan.net
- 6In the NAVIGATE‑PCI registry, treatment plans were modified in approximately 70% of patients after reviewing the Heartflow PCI Navigator. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.